{
    "2020-04-28": [
        [
            {
                "time": "2023-04-15",
                "original_text": "Novartis Stock Dives Alongside Pharma Peers Despite First-Quarter Beat",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Stock",
                        "Dives",
                        "Pharma",
                        "Peers",
                        "First-Quarter",
                        "Beat"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-04-15",
                "original_text": "Novartis (NVS) Q1 Earnings and Revenues Surpass Estimates",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Q1",
                        "Earnings",
                        "Revenues",
                        "Surpass",
                        "Estimates"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-15",
                "original_text": "Biotech Heavyweight Amgen Enters The Coronavirus Arena â€” But Is It A Buy?",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Heavyweight",
                        "Amgen",
                        "Coronavirus",
                        "Arena",
                        "Buy"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-04-15",
                "original_text": "The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Highlights",
                        "Intel",
                        "Novartis",
                        "Toyota",
                        "Motor",
                        "Union",
                        "Pacific",
                        "Biogen"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "pharmaceuticals",
                        "automobiles",
                        "transportation",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-04-15",
                "original_text": "Novartis Earnings Beat First-Quarter Views, Guidance Reaffirmed",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Earnings",
                        "Beat",
                        "First-Quarter",
                        "Views",
                        "Guidance",
                        "Reaffirmed"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-15",
                "original_text": "Novartis CEO: We Feel We Can Maintain Full Year Guidance",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "Maintain",
                        "Full",
                        "Year",
                        "Guidance"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-15",
                "original_text": "Novartis sales, profits rise in first quarter on COVID-19 buying rush",
                "features": {
                    "keywords": [
                        "Novartis",
                        "sales",
                        "profits",
                        "rise",
                        "first",
                        "quarter",
                        "COVID-19",
                        "buying",
                        "rush"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-15",
                "original_text": "Novartis posts first-quarter sales, profit beat as COVID-19 spurs prescriptions",
                "features": {
                    "keywords": [
                        "Novartis",
                        "posts",
                        "first-quarter",
                        "sales",
                        "profit",
                        "beat",
                        "COVID-19",
                        "spurs",
                        "prescriptions"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}